Latest news about Titan Biotech
Titan Biotech
398.50
+10.85(+2.80%)
Company Performance:
View Company Insights1D+2.80%
1M-0.44%
6M-16.66%
1Y+84.99%
5Y+503.60%
More news about Titan Biotech
14Aug 26
Titan Biotech Q1FY26 net profit up 53% YoY to ₹94.6 crore
Titan Biotech Ltd reported Q1FY26 standalone net profit of ₹94.6 crore, up 53% YoY, on revenue of ₹609.8 crore (+29%). Consolidated PAT rose 58% to ₹108.6 crore. The results reflect improved operating leverage and cost efficiency.
23Jun 26
Titan Biotech closes trading window from July 1 for Q1FY26 results
Titan Biotech Ltd closed its trading window on July 1, 2026, for insiders until 48 hours post Q1FY26 results announcement, adhering to SEBI regulations. The board meeting date for the June 2026 quarter results is pending.
01Jun 26
Titan Biotech FY26 net profit rises 50% to ₹2,744.72 lakh
Titan Biotech reported a 50.20% year-on-year increase in net profit to ₹2,744.72 lakh for FY26, with revenue from operations rising to ₹20,619.03 lakh. The board recommended a dividend of ₹0.50 per share and approved the re-appointment of a cost auditor.
20May 26
Titan Biotech board to consider FY26 results on May 30
Titan Biotech Limited announced its board meeting for May 30, 2026, to approve audited FY26 results and consider a dividend. The trading window for designated persons is closed from April 1 until 48 hours post-meeting.
06May 26
Titan Biotech Launches Second 'Saksham Niveshak' Campaign to Address Unclaimed Dividends
Titan Biotech Limited has announced its participation in the IEPFA's second 100 Days Campaign — 'Saksham Niveshak' — running from April 01, 2026 to July 09, 2026, aimed at helping shareholders claim unpaid or unclaimed dividends. The campaign follows an IEPFA circular dated March 27, 2026, and requires shareholders to update KYC details including PAN, bank account, nomination, and contact information. Shareholders must submit the relevant forms (ISR-1, ISR-2, SH-13, ISR-3) to the company's RTA, Beetal Financial & Computer Services Private Limited, before the July 9, 2026 deadline.
06May 26
Titan Biotech Limited Opens Special Window for Re-lodgement of Transfer Requests and Dematerialisation of Physical Shares
Titan Biotech Limited has announced a Special Window for re-lodgement of transfer requests and dematerialisation of physical shares, open from February 5, 2026 to February 4, 2027, pursuant to SEBI Circular dated January 30, 2026. The window covers physical securities sold or purchased prior to April 1, 2019, and also includes previously rejected or unattended transfer requests. Investors who missed the earlier deadline of January 6, 2026 may submit documents to BEETAL Financial & Computer Services Pvt. Ltd., New Delhi. The disclosure was filed with BSE Limited on May 6, 2026.
04May 26
Titan Biotech Limited Submits Annual Secretarial Compliance Report for Financial Year Ended March 31, 2026
Titan Biotech Limited filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, with BSE Limited on May 4, 2026, pursuant to Regulation 24A of SEBI (LODR) Regulations, 2015. The report, issued by Practicing Company Secretary Mr. Amit Anand (M No: ACS-13409, CP No: 17101) on April 24, 2026, confirmed full compliance across all applicable SEBI regulations with no deviations, violations, or regulatory actions recorded. Key compliance areas including secretarial standards, insider trading norms, related party transactions, and website disclosures were all found to be in order. No material subsidiary was identified during the review period, and no observations from previous reports remained unaddressed.
06Apr 26
Titan Biotech Limited Files Regulatory Notice for Lost Share Certificates with BSE
Titan Biotech Limited filed a regulatory notice with BSE Limited on 06/04/2026 regarding newspaper advertisements for lost share certificates. The filing, submitted by Compliance Officer Charanjit Singh, includes publications in English and Hindi newspapers and will be hosted on the company's website, demonstrating standard corporate governance compliance for the ISO 9001:2015 certified company.
04Apr 26
Titan Biotech Limited Submits SEBI Compliance Certificate for Q4 FY26
Titan Biotech Limited filed its Q4 FY26 compliance certificate under SEBI Regulation 74(5) on April 4, 2026, covering the quarter ended March 31, 2026. The certificate, prepared based on confirmation from registrar Beetal Financial & Computer Services (P) Ltd, confirms proper handling of dematerialization processes including timely processing of securities, mutilation of certificates, and substitution of depositories as registered owners within mandated timeframes.
Industry Peers
Pidilite Industries
SRF
Gujarat Fluorochemicals
Navin Fluorine International
Himadri Speciality Chemical
Aether Industries
Deepak Nitrite
Atul
Aarti Industries
Fine Organic Industries
1,482.00
(+1.50%)
2,519.50
(+1.38%)
4,476.80
(+0.83%)
8,352.50
(-0.77%)
659.95
(-0.02%)
1,748.10
(+0.23%)
1,621.90
(+2.39%)
5,882.50
(-0.68%)
460.15
(-3.74%)
5,410.50
(+0.56%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
